United Kingdom 2019: Triple-Negative Breast Cancer Key Opinion Leader (KOL) Interview - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 21, 2019--
The “Triple-Negative Breast Cancer KOL Interview - UK” report has been added to ResearchAndMarkets.com’s offering.
A UK-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple-negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, capivasertib, ipatasertib, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.
Highlights from the interview include:
For more information about this report visit https://www.researchandmarkets.com/r/90eggk
View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005772/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/21/2019 11:56 AM/DISC: 11/21/2019 11:56 AM